US stock · Healthcare sector · Biotechnology
A
ACADIA Pharmaceuticals Inc.
ACAD
NASDAQ23.97
USD
-0.64
(-2.60%)
Market Closed
-27.36P/E
- -Forward P/E
-1.12P/E to S&P500
3.898BMarket CAP
- -Div Yield
Upcoming Earnings
7 Aug-11 Aug
Shares Short
5/15/23
9.97M
Short % of Float
8.23%
Short % of Shares Outs.
6.13%
% Held by Insiders
0.23%
% Held by Institutions
97.70%
Beta
0.54
PEG Ratio
-1.79
52w. high/low
26.04/12.24
Avg. Daily Volume
1.61M
Return %
Stock
S&P 500
1 year
44.59
3.92
3 years
(46.97)
37.71
5 years
37.79
56.01
Scale: |
High
Low
13.46
0.72
6.60
0.75
2.00
0.65
3.30
0.90
6.54
1.06
29.73
4.60
33.49
15.64
51.99
29.45
42.49
16.64
41.20
25.06
32.99
12.77
53.70
15.72
58.72
30.02
55.85
15.68
28.05
12.24
26.04
15.77
Currency: USD
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
Revenue per share
0.21
0.04
0.17
1.09
0.04
0.09
0.01
0.00
0.00
0.15
1.02
1.77
2.30
2.81
3.08
3.20
3.21
Earnings per share
(1.60)
(1.73)
(1.20)
0.39
(0.44)
(0.38)
(0.44)
(0.95)
(1.63)
(2.34)
(2.36)
(1.94)
(1.60)
(1.79)
(1.07)
(1.34)
(0.91)
FCF per share
(1.57)
(1.75)
(0.37)
(0.28)
(0.38)
(0.39)
(0.38)
(0.68)
(1.23)
(1.90)
(1.78)
(1.34)
(1.03)
(0.91)
(0.81)
(0.71)
(0.34)
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
CAPEX per share
0.01
0.01
0.00
- -
0.00
- -
0.01
0.00
0.02
0.08
0.01
0.02
0.01
0.05
0.01
- -
- -
Book Value per sh.
3.24
1.43
0.32
0.77
0.45
1.54
2.12
3.18
1.99
4.47
2.73
3.78
4.75
3.99
3.44
2.48
2.52
Comm.Shares outs.
35
37
37
39
52
55
86
97
101
116
123
127
147
157
157
162
162
Avg. annual P/E ratio
(8.0)
(3.3)
(1.6)
3.1
(3.6)
(5.9)
(36.6)
(25.8)
(23.0)
(12.5)
(13.9)
(10.4)
(19.0)
(25.4)
(25.4)
(14.1)
(27.4)
P/E to S&P500
(0.5)
(0.2)
(0.0)
0.2
(0.2)
(0.4)
(2.1)
(1.4)
(1.1)
(0.6)
(0.6)
(0.4)
(0.8)
(0.7)
(0.8)
(0.7)
(1.1)
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue (m)
8
2
6
42
2
5
1
0
0
17
125
224
339
442
484
517
520
Operating margin
(829.3)%
(4,212.5)%
(710.5)%
35.8%
(1,105.6)%
(425.6)%
(3,344.7)%
(77,691.7)%
(269,855.7)%
(1,574.1)%
(234.1)%
(110.6)%
(72.7)%
(64.9)%
(35.2)%
(43.2)%
(31.9)%
Depreciation (m)
1
1
1
1
0
0
0
0
1
2
3
3
3
3
3
(1)
- -
Net profit (m)
(56)
(64)
(45)
15
(23)
(21)
(38)
(92)
(164)
(271)
(289)
(245)
(235)
(282)
(168)
(216)
(146)
Income tax rate
- -
- -
- -
- -
- -
- -
- -
- -
(0.2)%
(0.5)%
(0.4)%
(0.5)%
(0.4)%
(0.2)%
(0.2)%
(1.2)%
(0.5)%
Net profit margin
(746.4)%
(4,040.5)%
(705.5)%
35.9%
(1,101.4)%
(424.9)%
(3,314.2)%
(77,062.5)%
(269,578.7)%
(1,565.9)%
(231.7)%
(109.6)%
(69.4)%
(63.7)%
(34.7)%
(41.8)%
(28.2)%
Working capital (m)
112
51
34
32
26
103
181
309
197
505
324
467
685
612
522
382
279
Long-term debt (m)
1
0
0
0
- -
- -
- -
- -
- -
- -
- -
- -
6
44
56
53
51
Equity (m)
114
53
12
30
23
85
182
309
200
518
335
479
699
627
541
400
374
ROIC
- -
- -
- -
- -
- -
(20.3)%
(20.8)%
(29.9)%
(82.2)%
(52.3)%
(86.3)%
(51.0)%
(31.6)%
(40.6)%
(27.7)%
(46.7)%
(38.3)%
Return on capital
(41.9)%
(99.1)%
(90.7)%
39.4%
(70.9)%
(19.2)%
(20.1)%
(28.4)%
(74.0)%
(48.1)%
(75.0)%
(45.2)%
(28.5)%
(35.1)%
(23.8)%
(36.3)%
(25.1)%
Return on equity
(49.5)%
(121.2)%
(372.7)%
51.0%
(97.4)%
(24.5)%
(20.8)%
(29.9)%
(82.3)%
(52.4)%
(86.3)%
(51.2)%
(33.7)%
(44.9)%
(31.0)%
(53.9)%
(39.0)%
Plowback ratio
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Div.&Repurch./FCF
- -
- -
- -
7.7%
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Capital Structure
8 May · 2023 | Q1
All numbers in millions
Total liabilities
$ 281
Total assets
$ 655
Long-term debt
$ 51
Cash and equiv.
$ 291
Goodwill
$ - -
Retained earnings
$ (2,413)
Common stock
162
Enterprise Value
$ 3,659
Working Capital
Currency: USD, in millions
2020
2021
2022
Cash & Investments
632
521
417
Receivables
50
65
63
Inventory
10
8
7
Other
26
(155)
(190)
Current assets
718
618
508
Acc. Payable
8
7
13
Debt due
5
8
- -
Other
92
81
113
Current liabilities
106
96
126
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
6.83%
24.55%
3,218.99%
Cash flow
(10.05)%
(9.42)%
23.17%
Earnings
28.66%
0.98%
31.31%
Dividends
- -
- -
- -
Book value
(25.97)%
(1.02)%
21.94%
Insider Trading
Type
Shares
Date
Baker Bros. Advisors Lp
Purchase
7,645
05/22/23
Baker Bros. Advisors Lp
Purchase
82,148
05/22/23
Baker Bros. Advisors Lp
Purchase
3,781
05/22/23
Baker Bros. Advisors Lp
Purchase
40,632
05/22/23
Baker Bros. Advisors Lp
Exempt
12,500
05/23/23
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2021
107
115
132
131
484
2022
115
135
131
136
517
2023
118
- -
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2021
(0.42)
(0.28)
(0.09)
(0.27)
(1.07)
2022
(0.70)
(0.21)
(0.17)
(0.26)
(1.34)
2023
(0.27)
- -
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Biotechnology
CEO:
Mr. Stephen R. Davis J.D.
Full-time employees:
540
City:
San Diego
Address:
12830 El Camino Real
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.